APA (7th ed.) Citation

Tursi, A., Mocci, G., Costa, F., Ceccarelli, L., Savarino, E., De Barba, C., . . . Maconi, G. (2026). Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: Data from a real-world study. Intestinal Research, 24(2), 341. https://doi.org/10.5217/ir.2025.00067

Chicago Style (17th ed.) Citation

Tursi, Antonio, et al. "Filgotinib Effectiveness and Safety as Second or Third-line Therapy in Patients with Ulcerative Colitis: Data from a Real-world Study." Intestinal Research 24, no. 2 (2026): 341. https://doi.org/10.5217/ir.2025.00067.

MLA (9th ed.) Citation

Tursi, Antonio, et al. "Filgotinib Effectiveness and Safety as Second or Third-line Therapy in Patients with Ulcerative Colitis: Data from a Real-world Study." Intestinal Research, vol. 24, no. 2, 2026, p. 341, https://doi.org/10.5217/ir.2025.00067.